Trevi Therapeutics, Inc. (TRVI) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 8.74M USD | Liabilities, Current |
| Cash and equivalents | 54.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 264.57M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $8.74M | $54.30M | $264.57M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $7.12M | $19.41M | $152.37M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $9.75M | $18.91M | $169.35M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $9.04M | $56.87M | $138.06M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $9.24M | $117.06M | $86.83M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $6.87M | $19.37M | $83.88M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $10.51M | $34.10M | $73.53M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $9.12M | $16.05M | $49.44M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $6.75M | $12.96M | $56.53M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $5.28M | $13.81M | $59.01M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $5.82M | $32.40M | $50.57M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $5.17M | $25.96M | $62.90M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $4.71M | $13.75M | $80.40M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $13.20M | $11.65M | $99.61M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $13.40M | $12.59M | $107.92M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $14.64M | $66.57M | $59.03M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $15.43M | $24.70M | $53.16M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $12.87M | $29.11M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $12.72M | $36.83M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $9.91M | $29.32M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $9.41M | $36.42M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $5.34M | $41.57M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $5.55M | $45.00M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $6.10M | $53.29M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $6.77M | $44.18M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $7.21M | $52.64M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $5.20M | $57.31M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $5.03M | $63.52M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $7.11M | $71.39M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.67M | $12.95M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.68M | $7.20M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $13.53M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $7.06M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $15.96M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $22.02M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |